Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)-Reference-Cited by-同舟云学术

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

Published:2016-11-22 Issue:1 Volume:79 Page:29-36
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nakamura Masato,Aoyama Toru,Ishibashi Keiichiro,Tsuji Akihito,Takinishi Yasutaka,Shindo Yoshiaki,Sakamoto Junichi,Oba Koji,Mishima Hideyuki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3203-7.pdf

Reference16 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914

3. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865

4. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825–3829

5. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301–311

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Targeted Therapy for Metastatic Colorectal Cancer;International Journal of Molecular Sciences;2023-01-15

2. Therapeutic Targeting of RAS Mutant Cancers;2022-08-26

3. Chemoresistance in Colorectal Malignancies: Molecular Mechanisms and Strategies to Overcome.;Colon Cancer Diagnosis and Therapy Vol. 3;2022

4. The Role of Wild-Type RAS in Oncogenic RAS Transformation;Genes;2021-04-28

5. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment;Oncology Letters;2021-01-14